Daxor Net Income Over Time
| DXR Stock | USD 12.54 0.33 2.70% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Daxor Performance and Daxor Correlation. Can Health Care Equipment & Supplies industry sustain growth momentum? Does Daxor have expansion opportunities? Factors like these will boost the valuation of Daxor. Projected growth potential of Daxor fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Daxor demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Quarterly Earnings Growth (0.36) | Earnings Share 0.16 | Revenue Per Share | Quarterly Revenue Growth (0.74) | Return On Assets |
The market value of Daxor is measured differently than its book value, which is the value of Daxor that is recorded on the company's balance sheet. Investors also form their own opinion of Daxor's value that differs from its market value or its book value, called intrinsic value, which is Daxor's true underlying value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Because Daxor's market value can be influenced by many factors that don't directly affect Daxor's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Daxor's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Daxor should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Daxor's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Daxor and related stocks such as Nephros, CervoMed, and Great Elm Group Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEPH | (1.1 M) | (2.4 M) | (3.3 M) | (3.7 M) | (7.4 M) | (3.1 M) | (3 M) | (809 K) | (3.4 M) | (3.4 M) | (4.8 M) | (4.1 M) | (7.4 M) | (1.6 M) | 74 K | 85.1 K | 89.4 K |
| CRVO | 200 K | (22.6 M) | (6.9 M) | (2.5 M) | (14.4 M) | (6.7 M) | (18 M) | (1.4 M) | (18.4 M) | (11.8 M) | (14.2 M) | (24.1 M) | (15.6 M) | (2.2 M) | (16.3 M) | (14.7 M) | (13.9 M) |
| GEG | (10.6 M) | 14.6 M | (47.6 M) | 433 K | (41.8 M) | 9.4 M | (15.2 M) | (11.1 M) | (6.9 M) | (13 M) | (7.3 M) | (14.9 M) | 27.7 M | (1.4 M) | 12.9 M | 14.8 M | 15.6 M |
| GANX | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (1.1 M) | (2.2 M) | (3.6 M) | (13.9 M) | (17.6 M) | (22.3 M) | (20.4 M) | (18.4 M) | (19.3 M) |
| NRXP | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | (105 K) | 66.1 K | 408.4 K | (51.8 M) | (93.1 M) | (39.8 M) | (30.1 M) | (25.1 M) | (22.6 M) | (23.7 M) |
| ACET | 13.5 M | 9 M | 17 M | 22.3 M | 22.3 M | 29 M | (1000) | (33.8 M) | (9.3 M) | (28.1 M) | (36.7 M) | (62 M) | (69.8 M) | (142.7 M) | (117.1 M) | (105.4 M) | (100.1 M) |
| ADAG | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.3 M) | (16.4 M) | (73.2 M) | (80 M) | (18.9 M) | (33.4 M) | (30.1 M) | (31.6 M) |
| LITS | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (54.5 M) | (31.8 M) | 17.8 M | (15.9 M) | (18.3 M) | (19.3 M) |
| BEAT | (12.7 M) | (61.4 M) | (12.2 M) | (7.3 M) | (9.8 M) | 7.4 M | 53.4 M | (16 M) | 42.8 M | (778 K) | (1.3 M) | (4.4 M) | (12.8 M) | (14.6 M) | (19.4 M) | (22.4 M) | (21.2 M) |
| XBIT | (15.2 M) | (15.2 M) | (15.2 M) | (9.9 M) | (21.7 M) | (37.5 M) | (52.8 M) | (33.1 M) | (21.1 M) | 668.6 M | (11.2 M) | (17.4 M) | (32.9 M) | (24.6 M) | (38.5 M) | (44.3 M) | (42.1 M) |
Daxor and related stocks such as Nephros, CervoMed, and Great Elm Group Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Daxor financial statement analysis. It represents the amount of money remaining after all of Daxor operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Daxor | DXR |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 109 Meco Lane, |
| Exchange | NASDAQ Exchange |
USD 12.54
Additional Tools for Daxor Stock Analysis
When running Daxor's price analysis, check to measure Daxor's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Daxor is operating at the current time. Most of Daxor's value examination focuses on studying past and present price action to predict the probability of Daxor's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Daxor's price. Additionally, you may evaluate how the addition of Daxor to your portfolios can decrease your overall portfolio volatility.